Title
<tex>$_AS03_{A}$</tex>&#8208;adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age <tex>$_AS03_{A}$</tex>&#8208;adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age
Author
Faculty/Department
Faculty of Medicine and Health Sciences
Publication type
article
Publication
Chicago, Ill. ,
Subject
Human medicine
Source (journal)
Clinical infectious diseases. - Chicago, Ill.
Volume/pages
51(2010) :6 , p. 668-677
ISSN
1058-4838
ISI
000281143400005
Carrier
E
Target language
English (eng)
Full text (Publishers DOI)
Affiliation
University of Antwerp
Abstract
Background.Vaccination of high&#8208;risk groups was started shortly after the emergence of the influenza A (H1N1) 2009 pandemic virus. Methods.Healthy adults were enrolled into 2 age strata: 1860 years and >60 years, and received monovalent influenza vaccine containing 3.75 μg of A/California/2009 (H1N1) hemagglutinin antigen, adjuvanted with AS03A. Hemagglutination inhibition assaybased antibody titers against H1N1 vaccine were assessed after 1 vaccine dose (primary endpoint), after which subjects were randomized 1:1 to receive no further vaccination or a second dose. Immunogenicity endpoints were European licensure criteria for influenza vaccines. Exploratory analyses assessed the effect of previous seasonal influenza vaccination on responses to the H1N1 vaccine. Results.Licensure criteria for immunogenicity were fulfilled after 1 dose of H1N1 vaccine ( ). For subjects 1860 years of age, previous vaccination against seasonal influenza within the preceding 2 seasons resulted in significantly lower geometric mean titers (adjusted for baseline antibody titer) after 1 or 2 doses of H1N1 vaccine ( and , respectively). Transient mild or moderate injection&#8208;site pain was reported by 87.5% and 65.0% of subjects 1860 years of age and >60 years of age, respectively, after the first dose, and in 63% of subjects overall after the second dose. Conclusions.A single dose of 3.75 μg hemagglutinin antigen, AS03A&#8208;adjuvanted H1N1 2009 vaccine was immunogenic and well tolerated in adults. In exploratory analyses (of subjects 1860 years of age), postvaccination antibody titers were lower in subjects who had previously received seasonal influenza vaccination, compared with those who had not. This phenomenon warrants further investigation.
E-info
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000281143400005&DestLinkType=RelatedRecords&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000281143400005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000281143400005&DestLinkType=CitingArticles&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
Handle